Literature DB >> 8560404

High lipoprotein (a) levels in chronic hemodialysis patients are closely related to the acute phase reaction.

K Kario1, T Matsuo, H Kobayashi, M Matsuo, R Asada, M Koide.   

Abstract

To study the mechanism underlying the high lipoprotein (a) [Lp(a)] level in uremic patients on chronic hemodialysis, we investigated the levels of Lp(a), acute phase reactants (C-reactive protein and sialic acid), and interleukin-6 (IL-6) in 54 dialysis patients. The mean [95% CI] Lp(a) level was increased in the hemodialysis patients compared with the 30 controls (30 [25-36] vs. 18 [14-23] mg/dl, p < 0.005). Among dialysis patients, 46% had an Lp(a) level > 30 mg/dl, which was significantly higher than the percentage in the control group (17%). The levels of C-reactive protein, sialic acid, and IL-6 were also increased in dialysis subjects compared with controls (200 [134-299] vs. 37 [24-58] micrograms/dl, p < 0.0001; 63 [59-66] vs. 54 [52-56] mg/dl, p < 0.002; and 9.2 [7.8-11] vs. 5.5 [5.0-6.1] pg/ml, p < 0.0005, respectively). The Lp(a) level was positively correlated with that of C-reactive protein (r = 0.415, p < 0.002), sialic acid (r = 0.426, p < 0.002), and IL-6 (r = 0.298, p < 0.05) in the hemodialysis patients, but not in the controls or non-dialysis uremic patients. The Lp(a) level in the dialysis patients was also positively correlated with activation markers of coagulation (thrombin-antithrombin III complex and plasmin-alpha 2-plasmin inhibitor complex, p < 0.005). These results indicate that the Lp(a) level is closely related to the acute phase reaction and hypercoagulability in chronic hemodialysis patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8560404

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Lipoprotein (a) does not participate in the early acute phase response to training or extreme physical activity and is unlikely to enhance any associated immediate cardiovascular risk.

Authors:  D J Byrne; I A Jagroop; H E Montgomery; M Thomas; D P Mikhailidis; N G Milton; A F Winder
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

2.  Lipoprotein (a) as an acute phase reactant in patients on chronic hemodialysis.

Authors:  Valdete Topciu Shufta; Luljeta Begolli; Emrush Kryeziu
Journal:  Bosn J Basic Med Sci       Date:  2010-02       Impact factor: 3.363

3.  A Systematic Literature Review of the Association of Lipoprotein(a) and Autoimmune Diseases and Atherosclerosis.

Authors:  I Missala; U Kassner; E Steinhagen-Thiessen
Journal:  Int J Rheumatol       Date:  2012-12-05

4.  The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury.

Authors:  Giuseppe Lippi; Ivan Szergyuk; Maria Helena Santos de Oliveira; Stefanie W Benoit; Justin L Benoit; Emmanuel J Favaloro; Brandon Michael Henry
Journal:  J Thromb Thrombolysis       Date:  2021-10-28       Impact factor: 5.221

5.  Serum Lipoprotein (a) on Postoperative Day 3: A Strong Predictor of Portal and/or Splenic Vein Thrombosis in Cirrhotic Patients With Splenectomy.

Authors:  Zhiyong Shi; Mingxia Zhang; Xiushan Dong; Jun Xu
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.